EUVIMEDEUVIMED entdecken
Crossref

The Efficacy and Toxicity of Bevacizumab in Combination With Gemcitabine in Patients With Recurrent Ovarian Cancer

Kerri S. Bevis, Jamie L. Erwin, Mack N. Barnes, J. Michael Straughn

Clinical Ovarian Cancer · 2011

DOI: 10.1016/j.cloc.2011.04.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Ovarian Cancer, 2011. Verfasst von Kerri S. Bevis und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Bevis, K. S., Erwin, J. L., Barnes, M. N., & Straughn, J. M. (2011). The Efficacy and Toxicity of Bevacizumab in Combination With Gemcitabine in Patients With Recurrent Ovarian Cancer. Clinical Ovarian Cancer. https://doi.org/10.1016/j.cloc.2011.04.004

Vancouver

Bevis KS, Erwin JL, Barnes MN, Straughn JM. The Efficacy and Toxicity of Bevacizumab in Combination With Gemcitabine in Patients With Recurrent Ovarian Cancer. Clinical Ovarian Cancer. 2011. doi:10.1016/j.cloc.2011.04.004

BibTeX
@article{Bevis2011,
  author = {Bevis, Kerri S. and Erwin, Jamie L. and Barnes, Mack N. and Straughn, J. Michael},
  title = {The Efficacy and Toxicity of Bevacizumab in Combination With Gemcitabine in Patients With Recurrent Ovarian Cancer},
  journal = {Clinical Ovarian Cancer},
  year = {2011},
  doi = {10.1016/j.cloc.2011.04.004}
}
Kostenlos starten →